Table 2 Statistical analysis on the mean change from baseline in WOMAC-Pain scores through scheduled visits
Interval | Treatment | Number | LS mean (SE) | 90% CI | Difference vs placebo | ||
|---|---|---|---|---|---|---|---|
LS mean (SE) | 90% CI | p-value | |||||
D3 - W12 | Placebo (N = 25) | 25 | − 0.47 (0.092) | (− 0.619, − 0.313) | |||
TLC599 12 mg (N = 26) | 26 | − 0.83 (0.090) | (− 0.984, − 0.685) | − 0.37 (0.129) | (− 0.583, − 0.154) | 0.0027 | |
TLC599 18 mg (N = 24) | 24 | − 0.64 (0.094) | (− 0.794, − 0.481) | − 0.17 (0.131) | (− 0.390, 0.047) | 0.0971 | |
D3 - W16 | Placebo (N =2 5) | 25 | − 0.48 (0.091) | (− 0.633, − 0.332) | |||
TLC599 12 mg (N = 26) | 26 | − 0.85 (0.088) | (− 0.999, − 0.705) | − 0.37 (0.127) | (− 0.580, − 0.158) | 0.0024 | |
TLC599 18 mg (N = 24) | 24 | − 0.62 (0.093) | (− 0.772, − 0.463) | − 0.13 (0.129) | (− 0.350, 0.080) | 0.1498 | |
D3 - W20 | Placebo (N = 25) | 25 | − 0.49 (0.091) | (− 0.647, − 0.343) | |||
TLC599 12 mg (N = 26) | 26 | − 0.85 (0.089) | (− 1.000, − 0.704) | − 0.36 (0.127) | (− 0.570, − 0.145) | 0.0033 | |
TLC599 18 mg (N = 24) | 24 | − 0.63 (0.093) | (− 0.782, − 0.472) | − 0.13 (0.130) | (− 0.349, 0.084) | 0.1558 | |
D3 - W24 | Placebo (N = 25) | 25 | − 0.51 (0.092) | (− 0.666, − 0.361) | |||
TLC599 12 mg (N = 26) | 26 | − 0.87 (0.089) | (− 1.014, − 0.718) | − 0.35 (0.128) | (− 0.565, − 0.139) | 0.0037 | |
TLC599 18 mg (N = 24) | 24 | − 0.62 (0.093) | (− 0.780, − 0.469) | − 0.11 (0.130) | (− 0.328, 0.106) | 0.1985 | |